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Background: Published studies investigating the association between XPC Lys939Gln polymorphism and colorectal
cancer (CRC) risk reported inconclusive results. We performed a meta-analysis to derive a precise estimation of the
relationship.
Methods: A comprehensive literature search was done in databases PubMed, EMBASE, and Cochrane library up to
December 2013. The association between XPC Lys939Gln polymorphism and CRC risk was assessed by odds ratios
(ORs) together with their 95% confidence intervals (CIs).
Results: Eight studies with 3,301 cases and 4,177 controls were included in the meta-analysis. We observed that the
XPC Lys939Gln polymorphism was correlated with an increased CRC risk when all studies were pooled into the
meta-analysis (Gln/lys vs. Lys/Lys: OR = 1.293, 95% CI 1.169–1.430, P = 0.000; Gln/Gln + Gln/lys vs. Lys/Lys: OR = 1.260,
95% CI 1.145–1.388, P = 0.000). In stratified analyses by ethnicity, smoking, and study quality, significant increased
CRC risk was found in Asians (Gln/lys vs. Lys/Lys: OR = 1.345, 95% CI 1.187–1.523, P = 0.000; Gln/Gln + Gln/lys vs.
Lys/Lys: OR = 1.317, 95% CI 1.170–1.484, P = 0.000), nonsmokers (Gln/Gln + Gln/lys vs. Lys/Lys: OR = 1.286, 95% CI
1.020–1.622, P = 0.033), and high quality studies. In subgroup analysis by source of control, significant increased CRC
risk was found in both hospital-based studies and population-based studies. However, in subgroup analysis
according to cancer location, no any significant association was detected.
Conclusions: This meta-analysis suggests that the XPC is a candidate gene for CRC susceptibility. The XPC Lys939Gln
polymorphism may play an important role in CRC development among Asians and nonsmokers. Further large and
well-designed studies are needed to confirm this association.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1665902729125948
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Colorectal cancer (CRC) is one of the most common
cancers and is the third leading cause of cancer-related
death worldwide [1,2]. In Europe and the USA, CRC
represents one of the main causes of cancer deaths [1,3].
In Asia, CRC is the fourth leading cause of mortality
by cancer, and its incidence is increasing [4,5]. In re-
cent years, the incidence of CRC is increasing in China,* Correspondence: qinxue919@126.com
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unless otherwise stated.which accounts for about 6.5% of total cancers in
urban areas and 4.6 % in rural areas [6]. Previous epi-
demiological studies have identified dietary factors,
such as consumption of meat, especially red meat, al-
cohol consumption, and cigarette smoking as possible
risk factors for the development of CRC [7,8]. However,
most individuals exposed to these known dietary risk fac-
tors never develop CRC while many CRC cases develop
among individuals without those known risk factors, sug-
gesting that other factors such as genetic factors also play
important roles in colorectal carcinogenesis.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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C (XPC) is one of the key members in the nucleotide ex-
cision repair (NER) pathway [9]. The NER pathway is
the primary mechanism for removal of adducts from
DNA, and thus is an important part of the cellular
defense against a large variety of structurally unrelated
DNA lesions. The XPC binds to HR23B and forms the
XPC-HR23B complex, which is involved in the DNA
damage recognition and DNA repair initiation in the
NER pathway and the binding of XPC to damaged DNA
is the rate-limiting step for NER [10-12]. The XPC gene
is located at chromosome 3p25 and contains 16 exons
and 15 introns. There are at least 687 reported single
nucleotide polymorphisms (SNPs) in the XPC gene region
(http://www.ncbi.nlm.nih.gov/snp/). Among all the identi-
fied SNPs, Lys939Gln polymorphism has received much
attention in recent years. It is a substitution of lysine for
glutamine in exon 15 of the XPC gene [13], and the
variant 939Gln allele have been reported to correlated
with reduced DNA repair activity and increased cancer
risk [14-16].
Over the last two decades, several molecular epi-
demiological studies have evaluated the association be-
tween XPC Lys939Gln polymorphism and CRC risk,
but the results remain controversial and inconclusive.
For genetic association studies that check candidate
polymorphisms, sample size is an important influencing
factor for study accuracy. Small sample size might have
insufficient power to explore a true association of mod-
est effect [17], especially for complex multifactorial dis-
ease such as CRC [18]. Combining data from all eligible
studies by meta-analysis has the advantage of increasing
statistical power and reducing random error and obtaining
precise estimates for some potential genetic associations.
Therefore, in this study, we conducted a quantitative
meta-analysis including all eligible studies.Methods
Search strategy
We searched Pubmed, Embase and Cochrane library
databases for all articles on the association between
XPC Lys939Gln polymorphism and CRC risk using the
following combined keywords: ‘xeroderma pigmentosum
group C’, ‘XPC’, ‘colon cancer’, ‘rectal cancer’ and ‘colorec-
tal cancer’. The latest search was done in December 2013,
without any language restriction. Additional articles were
identified through the references cited in the first series of
articles selected. Articles included in the meta-analysis
were in any language, with human subjects, published
in the primary literature and had no obvious overlap of
subjects with other studies. Among overlapping reports,
only the studies with more information on origin of
cases/controls were retained. The study was performedaccording to the proposal of Meta-analysis of Observa-
tional Studies in Epidemiology group (MOOSE) [19].
Selection criteria
The following inclusion criteria were used for literature
selection: (i) Case–control or cohort studies which eval-
uated the association between XPC Lys939Gln poly-
morphism and CRC risk; (ii) sufficient genotype data
were presented to calculate the odds ratios (ORs) and
95% confidence intervals (95% CIs); (iii) control popula-
tion did not contain malignant tumor patients. Major
reasons for exclusion of studies were (i) review, or meta-
analysis, or letter, or comment; (ii) duplicated studies, or
studies without raw data we need; and (iii) studies that
focused on HNPCC or FAP. Family–based studies of
pedigrees with several affected cases per family were also
excluded, because their analysis is based on linkage
considerations.
Data extraction
Two authors (Qiliu Peng and Xianjun Lao) independently
reviewed and extracted data from all eligible studies. Data
extracted included the first author, year of publication,
country of origin, ethnicity, genotyping method, matching
criteria, source of control, CRC ascertainment, total num-
bers of cases and controls and genotype frequencies of
cases and controls. Ethnic backgrounds were categorized
as Caucasian, and Asian. Smoking status (smoker or non-
smoker) was additionally recorded for stratified analysis.
Smokers included current smokers and former smokers.
Nonsmokers had never smoked. Cancer location was di-
vided into colon cancer and rectum cancer and was also
additionally recorded for the stratified analysis. To ensure
the accuracy of the extracted information, the two authors
checked the data extraction results and reached consensus
on all of the data extracted. If different results were gen-
erated, they would check the data again and have a dis-
cussion to come to an agreement. A third reviewer
(Weizhong Tang) was invited to the discussion if dis-
agreement still existed.
Quality score assessment
The quality of eligible studies was evaluated independently
by two authors (Qiliu Peng and Xue Qin) according to a
set of predefined criteria (Table 1) based on the scale of
Thakkinstian et al. [20]. The revised criteria cover the rep-
resentativeness of cases, source of controls, ascertainment
of CRC, total sample size, quality control of genotyping
methods, and Hardy-Weinberg equilibrium (HWE) in the
control population. Disagreements were resolved by con-
sensus. Scores ranged from 0 (lowest) to 10 (highest). Arti-
cles with scores equal to or less than 6 were considered
“low-quality” studies, whereas those with scores higher
than 6 were considered “high-quality” studies.
Table 1 Scale for quality assessment
Criteria Score
Representativeness of cases
Selected from cancer registry or multiple cancer center sites 2
Selected from oncology department or cancer institute 1




Population or community based 2
Both population-based and hospital-based/healthy volunteers/
blood donors
1.5
Hospital-based controls without colorectal cancer 1
Cancer-free controls without total description 0.5
Not described 0
Ascertainment of colorectal cancer
Histological or pathological confirmation 2






Quality control of genotyping methods
Clearly described a different genotyping assay to confirm the data 1
Not described 0
Hardy-Weinberg equilibrium
Hardy-Weinberg equilibrium in controls 1
Hardy-Weinberg disequilibrium in controls 0.5
No checking for Hardy-Weinberg disequilibrium 0
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Crude odds ratios (ORs) with 95% confidence intervals
(CIs) were used to assess the association between the
XPC Lys939Gln polymorphism and CRC risk. We evalu-
ated the XPC Lys939Gln polymorphism and CRC riskTable 2 Characteristics of eligible studies
First author
(year)




Pardini 2008 Czech Caucasian 532/532 PCR-RFLP
Gil 2012 Poland Caucasian 133/100 PCR-RFLP
Yue 2013 China Asian 428/450 PCR-RFLP
Aizat 2013 Malaysia Asian 255/255 PCR-RFLP
Engin 2010 Turkey Caucasian 110/116 PCR-RFLP
Wu 2011 China Asian 420/842 PCR-RFLP
Liu 2012 China Asian 1028/1085 PCR-RFLP
Hansen 2007 Denmark Caucasian 395/797 Endpoint reading
HC, Histologically confirmed; PC, Pathologically confirmed; NR Not reported; PB, Pop
control population; PCR–RFLP, Polymerase chain reaction-restriction fragment lengtusing co-dominants (Gln/Gln vs. Lys/Lys and Gln/lys vs.
Lys/Lys), recessive model (Gln/Gln vs. Gln/lys + Lys/
Lys), and dominant model (Gln/Gln + Gln/lys vs. Lys/
Lys). The Chi-square-based Q statistic test [21,22] was
used to evaluate the between-study heterogeneity. If the
result of the heterogeneity test was PQ < 0.10, the pooled
ORs were analyzed using the random-effects model [23].
Otherwise, the fixed-effects model [24] was selected.
Subgroup analyses were performed by ethnicity, source
of control, cancer location, smoking, and study quality.
Sensitivity analysis was conducted by sequential omission
of individual study to assess the robustness of the results.
Publication bias was assessed using a Begg’s funnel plot
and Egger’s regression asymmetry test [25]. If publication
bias existed, the Duval and Tweedie non-parametric “trim
and fill” method was used to adjust for it [26]. The distri-
bution of the genotypes in the control population was
tested for HWE using a goodness-of-fit Chi-square test.
All analyses were performed using Stata software, version
12.0 (Stata Corp., College Station, TX). All P values were
two-sided. To ensure the reliability and the accuracy of
the results, two authors entered the data into the statistical
software programs independently with the same results.
Results
Characteristics of studies
Based on the search criteria, ten studies investigating the
XPC Lys939Gln polymorphism and CRC susceptibility
were identified. Two of these articles were excluded be-
cause they did not present sufficient data for calculating
OR and 95% CI [27,28]. Manual search of references
cited in the eligible studies did not reveal any additional
articles. As a result, a total of 8 relevant studies contain-
ing 3,301 cases and 4,177 controls were included in the
meta-analysis [29-36] (Additional file 1: Figure S1). The
main characteristics of these studies were listed in
Table 2. Among these publications, four studies were
conducted in Caucasian descent [29,30,33,36], and four








HC HB Age and sex 8 0.165
NR HB Region 3.5 0.803
PC HB Age and sex 6 0.964
HC HB NR 5 0.316
NR HB NR 5 0.642
HC PB Age, sex, smoking and BMI 9 0.639
HC HB Age and sex 8 0.740
NR PB Sex 7.5 0.112
ulation–based; HB, Hospital–based; HWE, Hardy–Weinberg equilibrium in
h polymorphism.
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based studies [29-33,35]. Three of these studies presented
XPC Lys939Gln polymorphism genotype distributions ac-
cording to smoking status (smokers and nonsmokers).
The cases were histologically or pathologically confirmed
as CRC in five studies [29,31,32,34,35]. Controls were
mainly healthy or hospital-based populations and matched
with age and gender. The genotype distributions of the
controls in all of the included studies were consistent
with HWE.Meta-analysis
As shown in Table 3, we found that the XPC Lys939Gln
polymorphism was significantly correlated with increased
CRC risk when all studies were pooled into the meta-
analysis (Gln/lys vs. Lys/Lys: OR = 1.293, 95%CI 1.169–
1.430, P = 0.000; Gln/Gln +Gln/lys vs. Lys/Lys: OR =
1.260, 95% CI 1.145–1.388, P = 0.000). In subgroup ana-
lysis by ethnicity, significant increased CRC risk was found
in Asian populations (Gln/lys vs. Lys/Lys: OR = 1.345,
95%CI 1.187–1.523, P = 0.000, Figure 1; Gln/Gln +Gln/lys
vs. Lys/Lys: OR = 1.317, 95% CI 1.170–1.484, P = 0.000,
Figure 2), but not in Caucasian populations. In stratified
analysis according to study quality, significant increased
CRC risk was found in high quality studies (Gln/lys vs.
Lys/Lys: OR = 1.290, 95%CI 1.148–1.450, P = 0.000; Gln/
Gln +Gln/lys vs. Lys/Lys: OR = 1.248, 95%CI 1.117–
1.395, P = 0.000), but not in low quality studies. In sub-
group analysis by smoking status, significant increased
CRC risk was observed in nonsmokers (Gln/Gln +Gln/lys
vs. Lys/Lys: OR = 1.286, 95%CI 1.020–1.622, P = 0.033),
but not in smokers. In subgroup analysis according to
source of control, significant increased CRC risk was
found in both hospital-based studies (Gln/lys vs. Lys/Lys:
OR = 1.335, 95%CI 1.182–1.507, P = 0.000; Gln/Gln +
Gln/lys vs. Lys/Lys: OR = 1.282, 95% CI 1.142–1.439, P =
0.000) and population-based studies (Gln/lys vs. Lys/Lys:
OR = 1.204, 95%CI 1.003–1.444, P = 0.046; Gln/Gln +
Gln/lys vs. Lys/Lys: OR = 1.213, 95% CI 1.020–1.443, P =
0.029). However, in subgroup analysis according to cancer
location, statistical significant association was not detected
in both colon cancer patients and rectum cancer subjects.Heterogeneity analysis
Heterogeneity between studies was estimated using the
Chi-square-based Q test and the significance of which
was set at PQ < 0.10. There was no statistical significant
heterogeneity among studies when all eligible studies
were pooled into the meta-analysis. In subgroup analyses
according to ethnicity, source of control, cancer location,
smoking, and study quality, statistical significant hetero-
geneity was not observed in all subgroups (Table 3).Sensitivity analysis
Sensitivity analysis was performed by sequential omission
of individual studies. For analyses of pooling more than
three individual studies, the significance of the pooled
ORs was not influenced excessively by omitting any single
study (Figure 3), indicating that our results were statistical
robust.
Publication bias
Begg’s funnel plot and Egger’s test were performed to as-
sess the publication bias of literatures in all comparison
models. The shape of the funnel plot did not reveal any
evidence of obvious asymmetry (Figure 4). Then, the
Egger’s test was used to provide statistical evidence of
funnel plot symmetry. All the p values of Egger’s tests
were more than 0.05 (P = 0.660 for GlnGln vs. LysLys;
P = 0.584 for Glnlys vs. LysLys; P = 0.670 for dominant
model GlnGln + Glnlys vs. LysLys; and P = 0.627 for re-
cessive model GlnGln vs. Glnlys + LysLys), providing
statistical evidence for the funnel plots’ symmetry. The
results suggested that publication bias was not evident
in this meta-analysis.
Discussion
Maintenance of genomic integrity by DNA repair genes
is an essential component of normal cell homeostasis
necessary to cell growth, differentiation, and apoptosis
[37,38]. Increasing evidence indicating that reduced DNA
repair capacity, due to various DNA repair gene polymor-
phisms, is associated with increased risk and susceptibility
to human solid tumors [16,39,40]. XPC is a key member
in the NER pathway. It is involved in the recognition and
initiation of the genome repair of NER pathway [10,41,42].
Polymorphisms in the XPC gene may alter DNA repair
capacity of the NER pathway, which further play a critical
role in carcinogenesis [43]. To date, several epidemio-
logical studies have evaluated the association between
XPC Lys939Gln polymorphism and CRC risk, but the
results remain inconclusive. Meta-analysis has been rec-
ognized as an important tool to more precisely define
the effect of selected genetic polymorphisms on the risk
for disease and to identify potential important sources
of between-study heterogeneity [2]. To derive a more
precise estimation of the relationship, we performed
this meta-analysis. Our meta-analysis based on 8 case–
control studies suggested that the XPC Lys939Gln poly-
morphism contributes to increased CRC susceptibility.
In subgroup analysis by ethnicity, statistical significant
increased CRC risk was detected in Asians. However, no
significant association was found in Caucasians. Actually,
it might not be uncommon for the same polymorphism
playing different roles in cancer susceptibility among dif-
ferent ethnic populations, because cancer is a complicated
multi-genetic disease, and different genetic backgrounds
Table 3 Meta-analysis of XPC Lys939Gln polymorphism and colorectal cancer risk
Analysis No. of
studies
Homozygote Heterozygote Dominant model Recessive model
(Gln/Gln vs. Lys/Lys) (Gln/lys vs. Lys/Lys) (Gln/Gln + Gln/lys vs. Lys/Lys) (Gln/Gln vs. Gln/lys + Lys/Lys)
OR (95% CI) P/PQ OR (95% CI) P/PQ OR (95% CI) P/PQ OR (95% CI) P/PQ
Overall 8 1.134(0.979-1.315) 0.094/0.495 1.293(1.169-1.430) 0.000/0.943 1.260(1.145-1.388) 0.000/0.955 0.976(0.853-1.117) 0.722/0.211
Ethnicity
Caucasian 4 1.038(0.818-1.318) 0.758/0.885 1.200(0.983-1.426) 0.098/0.918 1.159(0.984-1.365) 0.077/0.951 0.915(0.740-1.133) 0.417/0.644
Asian 4 1.199(0.993-1.446) 0.059/0.180 1.345(1.187-1.523) 0.000/0.878 1.317(1.170-1.484) 0.000/0.978 1.078(0.809-1.436) 0.607/0.061
Source of control
HB 6 1.091(0.915-1.302) 0.333/0.399 1.335(1.182-1.507) 0.000/0.961 1.282(1.142-1.439) 0.000/0.945 0.922(0.785-1.082) 0.318/0.184
PB 2 1.243(0.950-1.627) 0.112/0.440 1.204(1.003-1.444) 0.046/0.528 1.213(1.020-1.443) 0.029/0.436 1.122(0.875-1.438) 0.366/0.545
Cancer location
Colon 2 1.105(0.809-1.510) 0.528/0.327 1.278(0.983-1.601) 0.093/0.851 1.234(0.996-1.528) 0.054/0.826 0.953(0.719-1.264) 0.738/0.226
Rectum 2 1.253(0.902-1.741) 0.179/0.482 1.200(0.941-1.532) 0.142/0.471 1.217(0.967-1.531) 0.094/0.419 1.140(0.847-1.534) 0.388/0.643
Smoking
Yes 3 1.299(0.841-2.006) 0.237/0.169 1.164(0.871-1.556) 0.305/0.825 1.118(0.900-1.389) 0.314/0.455 1.185(0.794-1.770) 0.405/0.261
No 2 1.256(0.620-2.542) 0.527/— 1.284(0.817-2.018) 0.279/— 1.286(1.020-1.622) 0.033/0.972 1.117(0.570-2.187) 0.747/—
Study quality
High quality 4 1.093(0.920-1.299) 0.313/0.547 1.290(1.148-1.450) 0.000/0.531 1.248(1.117-1.395) 0.000/0.680 0.950(0.811-1.114) 0.530/0.310
Low quality 4 1.257(0.944-1.674) 0.118/0.304 1.201(0.963-1.563) 0.091/0.996 1.278(0.971-1.552) 0.108/0.929 1.046(0.809-1.353) 0.733/0.128















Figure 1 Forest plot of subgroup analysis by ethnicity on the association between XPC Lys939Gln polymorphism and CRC risk using a
fixed-effect model (Glnlys vs. LysLys).
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http://www.diagnosticpathology.org/content/9/1/120may contribute to the discrepancy. Nevertheless, owing
to the limited number of relevant studies included in
the meta-analysis, the observed association between
XPC Lys939Gln polymorphism and CRC risk is likely to
be caused by chance because study with small sample
sizes may have insufficient statistical power to detect a
slight effect or may have generated a fluctuated risk
estimate. Currently there were only four studies on XPCFigure 2 Forest plot of subgroup analysis by ethnicity on the associa
fixed-effect model (dominant model GlnGln + Glnlys vs. LysLys).Lys939Gln polymorphism and CRC risk for Asian popula-
tions, and Caucasian populations, respectively. Therefore,
the observed results of our study should be interpreted
with caution.
When stratified according to the quality score of the
articles, statistical significant increased CRC risk was ob-
served in high quality studies but not in low quality
studies. The possible reason for the discrepancy may betion between XPC Lys939Gln polymorphism and CRC risk using a
Figure 3 Sensitivity analysis of XPC Lys939Gln polymorphism and CRC risk in the overall populations. This figures show the influence of
individual studies on the summary OR. The middle vertical axis indicates the overall OR and the two vertical axes indicate its 95% CI. Every hollow
round indicates the pooled OR when the left study is omitted in this meta-analysis. The two ends of every broken line represent the 95% CI.
A Glnlys vs. LysLys; B dominant model GlnGln + Glnlys vs. LysLys.
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low quality studies. In addition, genotyping methods
without quality control in studies of low quality should
be also considered when deciphering these inconsistent
results. In subgroup analysis according to the source of
control, statistical significant increased CRC risk was
found in both population-based studies and hospital-
based studies. However, the ORs and 95%CIs differ largely
in these two subgroups. The reason may be that the
hospital-based studies have a high risk of producing unre-
liable results because hospital-based controls may not al-
ways be truly representative of the general population.
Therefore, a methodologically preferable design, such as
using a proper and representative population-based high
quality study, is of great value in case–control studies.
It is well established that the carcinogenesis of CRC is
a result of the interaction between environmental factorsFigure 4 Funnel plots for publication bias of the meta-analysis on the
in the overall populations. A Glnlys vs. LysLys; B dominant model GlnGlnand genetic background [18,44]. Besides the role of gen-
etic variants, smoking behavior shows an important ef-
fect on the CRC susceptibility. It has been reported that
smoking increased CRC risk threefold [36]. It is thought
that smoking increased cancer risk due to chemicals
such as hydrocarbons, arylamines, nitrosamines, and the
formation of reactive oxygen species as by-products of
the above compounds [45] that are known to induce
bulky adducts, base damage, and DNA strand breaks.
DNA repair mechanisms are paramount in correcting
the changes on DNA and provide unmutated DNA while
replication goes on [46]. The XPC protein plays a crucial
role in repairing the DNA damage caused by tobacco
smoke. Individuals with the XPC variant genotype may
possess deficient DNA repair capability. Accordingly, the
XPC protein product may be less efficient in repairing
the DNA lesions induced by tobacco smoke, and therebyassociation between XPC Lys939Gln polymorphism and CRC risk
+ Glnlys vs. LysLys.
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http://www.diagnosticpathology.org/content/9/1/120could enhance the susceptibility, favoring the develop-
ment of CRC. Therefore, we carried out subgroup ana-
lysis according to smoking status. Our results showed an
increased CRC risk in nonsmokers but not in smokers,
which was inconsistent with the hypothesis above. The
results should be interpreted with caution because of the
limited numbers of the original studies. Therefore, further
studies concerning stratification for smoking are needed
to increase power for the association estimation.
Some possible limitations in this meta-analysis should
be acknowledged. First, in subgroup analysis by ethnicity,
the included studies regarded only Asians and Caucasians.
Data concerning other ethnicities such as Africans were
not found. Thus, additional studies are warranted to
evaluate the effect of this functional polymorphism on
CRC risk in different ethnicities, especially in Africans.
Second, our results were based on unadjusted estimates.
We did not perform the analysis adjusted for other covari-
ates such as age, drinking status, environment factors, and
so on, because of the unavailable original data of the
eligible studies. Third, in subgroup analyses by ethni-
city, cancer location, and smoking status, the sample
size of the subgroups was relatively small for stratified
analyses, which may lead to relatively weak power to
detect the real relationship.Conclusions
Our meta-analysis provided a more precise estimation
based on larger sample size compared with the individual
studies. Our study suggested that the XPC is a candidate
gene for CRC susceptibility. The XPC Lys939Gln poly-
morphism may play an important role in CRC develop-
ment especially among Asians and nonsmokers. In
order to further verify our findings, large well designed
epidemiological studies are warranted.Additional file
Additional file 1: Flow diagram of included studies for this
meta-analysis.
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